Life Sciences Archive » November, 2016

Life Sciences - November, 2016

314 articles

• Elan Investors Seek Initial OK For $135M SAC Capital Deal
• Ex-DePuy Exec Asks 11th Circ. To Reverse Noncompete Ban
• Plaintiffs Seek Big Punitives In 3rd J&J Hip Implant Trial
• LifeNet Seeks $17M Interest After 2014 $35M Patent Win
• Male Sex Enhancement Supplement Recalled
• Judge Drops 24 Knee Implant Cases From Zimmer MDL
• Bill On FDA Approvals, Mental Health Policy Clears House
• Life Tech Tells Justices Quantity Matters In Patent Case
• The Ethical Risks Of A Multijurisdictional Practice
• Malpractice Suit Says Allergan Schemed With Implant Doctors
• PE Investors Plug $260M Into China's Innovent Biologics
• Deals Rumor Mill: Johnson & Johnson, AppNexus, Albertsons
• Bombay Court Won't Send Contract Row To Arbitration
• Doc In $20.3M Patent Suit Slams Claim He Withheld Evidence
• Braintree Labs Fights Ferring False Ad Trial Delay
• Phase-Down Of HFCs Depends On Trump Administration
• 3rd Circ. Won't Rethink Mylan's Doryx Product-Hopping Loss
• Boston Scientific Hit With IP Suit Over Pain Treatment Tech
• 3 Key Takeaways Buried In 1st Circ.'s Nexium Ruling
• Lidoderm Buyers, Payors Near Cert. In Pay-For-Delay MDL
• Herbalist Says Las Vegas Company Infringing Trademarks
• Illumina Can Add Patent To DNA Sequencer Infringement Case
• J&J Unlikely To Cut Risperdal Deals As Appeals Play Out
• Gov't To Ask If Chemical Weapons Treaty Affects Businesses
• FDA Warning Wire: Grimy Galleys On Riverboats
• Whistleblower In $785M Pfizer FCA Deal Agrees To Fees Split
• 11th Circ. Faults Service Delay In Tossing J&J Hip Suit
• And Now A Word From The Panel: MDL Venue Choices
• Intuitive Can Be Sued For Stolen Da Vinci Robot Payments
• How Law Firms Are Using Analytics To Reduce Write-Offs
• Doctor Defends Sanofi TCPA Suit From Claims It's Untimely
• Deals Rumor Mill: Johnson & Johnson, WGL Holdings, Avaya
• A Look At The On-Sale Bar: Part 2 — Best Business Practices
• A Review Of Key Cases Against Executives In Q3
• $2.75M Deal Settling 9-Year-Old Amgen ERISA Suit Nears OK
• 1st Circ. Revives Part Of Securities Suit Against Ariad
• PharMerica Escapes Federal FCA Claims Over Kickbacks
• Theranos Stuck By Investor Suit Saying It Lied About Testing
• Celgene Wants PTAB Rethink On Bass' Cancer Drug IP Win
• Theranos Wants Most Claims Tossed In $96M Hedge Fund Suit
• Kimberly-Clark's Stay Bid Assailed In Surgery Gown Suit
• Post Unit Hit With False Ad Suit Over Joint-Health Products
• Antibody Drug Developer Kymab Snags $100M From Investors
• GCs Say This Firm Is The Most Arrogant
• A Look At The On-Sale Bar: Part 1 — The Helsinn Debate
• In Congress: 3 Priorities
• The Missing American Jury
• Bio-Rad Says Ex-GC Faked FCPA Concerns To Save Job
• Idenix, Gilead To Battle Over Hepatitis IP At Trial
• 6th Circ. Denies Payment Bid In Dow Corning Implant Deal
• Acorda, AstraZeneca Tell Justices To Skip ANDA Venue Case
• Eli Lilly Abandons Alzheimer's Drug After Failed Trial
• PTAB Invalidates Claims In Durezol Eye Drops Patent
• 3rd Circ. Won't Review Atty Sanctions In Fish Oil Suit
• Sheller PC Wants 3rd. Circ. To Rehear Risperdal Row
• EU OKs Abbott's $25B Acquisition Of St. Jude With Caveats
• No 3rd Circ. Rehearing In Zimmer Hip Replacement Case
• Investcorp Drops $250M On Boston, Denver Properties
• Employer Takeaways From Abbott's $4.25M Age-Bias Verdict
• Neovasc Escapes Investor Suit Over $70M Trial Loss
• Shkreli Atty Rips Retrophin Over Katten Doc Privilege Row
• 1st Circ. Won't Revive Takeda FCA Actos Kickbacks Suit
• Actavis Infringed Orexo's Zubsolv Patent, Del. Judge Rules
• FDA Warning Wire: Peanut Allergy Claims Get A Shellacking
• INTA Pushes High Court To Take Flanax Trademark Case
• Consumer's False Ad Suit Falls Flat, Supplement Maker Says
• On Second Thought, Court Drops UBS From Defamation Suit
• Consumers Says Nivea Can't Slip Out Of Lotion Suit
• Ala. Justices Trim Pharmacy's Tainted-Drug Coverage By $3M
• Expert OK To Testify In GSK Suit By Reed Smith Atty's Widow
• Arch Venture Partners Seeks $550M With Upsized Fund Target
• J&J Wants Philly Invokana Cases In NJ Federal Court
• Plumlee V. Pfizer: Don't Underestimate Statute Of Limitations
• Law360 MVP Awards Go To Top Attorneys From 76 Firms
• 8 States Have Legalized Marijuana In 8 Different Ways
• Avoiding Law Firm BYOD Risks: Tips For Securing Devices
• Female Condom Co. Merged Without Investors' OK, Suit Says
• 1st Circ. Won't Revive Nexium Pay-For-Delay Suit
• Mylan, Par, Others Rigged Divalproex Sodium ER Prices: Suit
• Shkreli's Ex-Atty Wants Detailed Charges, Citing Gov't Error
• Mylan Refuses To Testify At Senate's EpiPen Rebate Hearing
• Fla. Doctor Convicted Of Using Foreign, Unlicensed Drugs
• Kimberly-Clark Seeks To Freeze Gown Trial For Cert. Appeal
• Antitrust Agencies Can Curb High Prices, Vestager Says
• Merger Control Update: It Ain't Over Till It's Over
• 4 Ways Lawyers Can Improve Their Marketing
• What To Expect In The Remaining Days Of The 114th Congress
• GSK, Others Back Bristol-Myers In Plavix Jurisdiction Row
• 6th Circ. Axes Stryker's $8.6M Knee Implant Coverage Win
• Adapt Pharma Urges FDA Hurdles For Teva Overdose Generic
• Thermolife Bristles at 'Patent Troll' Label In Amino Patent Suit
• Sessions' History Is Short But Not Silent On Antitrust
• Health Hires: Merchant & Gould, Davis Wright, Greenspoon
• Medical Robotics Co. Myomo Plans 'Mini-IPO'
• FDA Pauses Stronger Lab Test Oversight
• Taxation With Representation: Wachtell, Kirkland, Simpson
• 6 More States Join Suboxone Product-Hopping Lawsuit
• FDA Weighs Pros And Cons Of Off-Label Promotion
• Beyond Bean Counting: How Legal Can Add True Value
• The Unintended Impact Of DEA's New Registration Policy
• Procaps Wants Antitrust Suit Over $255M Merger Revived
• Amgen Investor Defends Decade-Old Derivative Suit
• Pfizer Sues Texas Agency For Releasing Drug Rebate Info
• Fed. Circ. Affirms Generics' Win In Kidney Drug Patent Suit
• Hearing Aid Patent Case Sent Back By Fed. Circ. Under Halo
• Ardian Enters Exclusive Talks To Acquire Unither Pharma
• Chicago Passes Strict Licensing Standards For Pharma Reps
• Labaton Attys Used False Witness Statements, Intuitive Says
• Judge Nixes Some Claims In Meningitis Outbreak Litigation
• Duane Morris & Selvam Taiwan Opens In Taipei
• Pharmacist Admits Running $2.4M Prescription Fraud Scheme
• GSK Defends Suicide Expert In Trial Over Reed Smith Death
• Apotex Pushes To Have Late Sandoz Subpoena Tossed
• Bharara Unveils Charges Against Ex-Valeant, Philidor Execs
• Ex-Amerisource Employee Claims Its Lies Cost Him Jobs
• Vitamin Buyers Try Again On False 'Made In USA' Cert. Bid
• Stock, Screen, Steer, Substitute To Win Bellwether Trials
• Patients Want 2 UnitedHealth Clawback Suits Combined
• Post-Election Thoughts On Antitrust
• OPINION: The US Supreme Court In 2017
• Shkreli Says Retrophin Has Waived Privilege For Katten Docs
• 9th Circ. Backs $15M Medtronic Verdict Over Pabban Deal
• Teva Beats Merck Infringement Suit Over Valid Patent
• Whistleblowers Fight To Revive Medicare Suit In 11th Circ.
• Senator Wants DOJ To Testify At EpiPen Rebate Hearing
• Pharmacist Facing Murder Charges Seeks MDL Docs
• Affordable Drug Group Blasts Pozen Patent At PTAB
• Zuckerman Spaeder Nabs Obama's Ex-Top Health Atty
• Simpson Thacher Leads Banks In Samsung Biologics' $2B IPO
• Work For GSK Got Pair Jailed In China, Suit Says
• FTC Aims To Be Stricter On Homeopathic Medicine Claims
• UnitedHealth Sued Again Over Prescription Copay Clawbacks
• Teva Pharmaceuticals Earmarks $520M To End FCPA Claims
• FDA Draft Sheds Light On Software As A Medical Device
• A Primer On The Presidential Appointee Vetting Process
• Merging Law Firms: Think Before You Tie The Knot
• Abbott, Alere Report Records Deal But Merger Issues Linger
• Once Sizzling, Silicon Valley Venture Financings Level Out
• FDA Warning Wire: Gripes Over Gluten, Deleted Data
• Fed. Circ. Says PTAB Wrongly Invalidated Surgical Patent
• Medical Supply Company Collars $1.2M Patent Judgment
• Kimberly-Clark Headed Toward Trial In Surgery Gown Suit
• SEC Settles Insider Trading Suit Against Ex-FDA Official
• Deals Rumor Mill: Snapchat, Viacom, Abbott Laboratories
• PTAB Upholds Patent In A First For Post-Grant Reviews
• How A Trump Administration Might Affect Product Liability
• Consumers Say GNC Can't Trash 'Slack Fill' Suit
• What's Next For US-Mexico Bilateral Trade Under Trump?
• Ex-Forest Sales Rep Defends Counsel In Namenda FCA Suit
• Zimmer Wants 142 Knee Cases Without Expert Reports Cut
• Merging Law Firms: Why Deals Fail Or Underperform
• Jury Hands Doctor $20.3M Verdict In Medtronic Patent Suit
• Alice Rejections Frustrating Patent Applicants, USPTO Told
• Merck Says Public Info Bars Whistleblower's Kickback Case
• PTAB Nixes Biosimilar Co.'s Bid For AbbVie Humira Review
• Mom Says Mo. Appeals Ruling Backs Her Depakote Claims
• Justices Won't Hear Drugmakers' OxyContin Patent Appeal
• Diplomat Pharmacy Faces Shareholder Suit Over Value Drop
• Cephalon, Teva Slam Pa. Opioid Off-Label Marketing Suit
• Deals Rumor Mill: Reynolds American, Novartis, AB InBev
• FCPA Enforcement On Near-Record Pace For 2016: Part 2
• Intellectual Property Under A Donald Trump Presidency
• What To Expect From The New Senate
• Impax Investor Says Drug Price-Fixing Probe Never Disclosed
• SEC Wins Insider Trading Trial Of Ex-InterMune Director
• Vitamin Health's False Ad Fight Not Covered, 6th Circ. Told
• 3rd Circ. Asked To Rehear Zimmer Hip Replacement Case
• Merging Law Firms: Beware Conflicts Of Interest
• Class Action Over Hep C Coverage Falls Flat, Colo. Says
• Man Vs. Machine: Or, Lawyers Vs. Legal Technology
• OPINION: The Verdict — A Rejection Of Politics As Usual
• Siemens Readies Public Listing For Health Care Unit
• Patent Legislation Has Uncertain Path In Trump Presidency
• Halo Applies To Trans Ova IP Suit, Judge Rules
• SEC Accused Of Race Profiling As Insider Trade Trial Ends
• McConnell Wants 21st Century Cures Act Passed In 2016
• GSK Seeks Sanctions Against Payors Quitting Avandia MDL
• Judge Will Hear GSK's Arguments To Dismiss Zofran MDL
• Amphastar Asks 9th Circ. To Revive Sanofi Patent FCA Suit
• Merging Law Firms: Why Hogan Lovells Has Worked
• Judge Gives Final OK To $3.3M Deal In Roka IPO Row
• Wright Beats Metal-Artificial-Hip Suit In Missouri
• Marijuana Tipping Point: California And Florida Lead The Way
• GSK Can't Duck Insurers' RICO Suit
• Benicar MDL Judge Says Docs Don't Show Cause Of Injuries
• 5 Takeaways From FDA's Off-Label Promo Forum
• Monkey Blood Supplier Pleads Guilty To False Labeling
• SEC Tells Jury Evidence Shows InterMune Exec Tipped Pal
• $15M Deal To End Adderall Buyers' Class Action Wins OK
• EU OKs Boehringer Animal Health Biz Buy, With Conditions
• Fed. Circ. Says PTAB Violated Process In NuVasive Review
• Czech Republic Takes $325M Blood Award To Supreme Court
• Pfizer Nabs 9th Circ. Victory In Zoloft False-Ad Suit
• FDA Will Study Drug Risk Info On Social Media
• Trial Ordered In Cryo-Chamber Arbitration Clause Row
• Pa. Man Gets Year For Role In $1.2M Embezzlement Scheme
• Pfizer Slams Appeal In Off-Label FCA Case In 1st Circ.
• Chamber Of Commerce, IRS Clash On Anti-Inversion Rule
• Impax Case Dies With Endo Pay-For-Delay Suit, FTC Says
• Animal Co. Gets PTAB Review Of Flea, Tick Treatment Patent
• Katten Muchin In Privilege Danger Zone With Shkreli Doc Bid
• Pharmacy Execs Linked To Meningitis Outbreak Get Probation
• GE's Barnes & Thornburg DQ Bid Is Misdirection, Court Told
• Calif. Voters Reject Measure To Limit Gov't Drug Costs
• Pharmacists Blast Feds' Bid For Redo In Meningitis Case
• Lab's Billing Claim Stiffed Marketers, Pa. Class Suit Says
• FCPA Enforcement On Near-Record Pace For 2016: Part 1
• Upcoming High Court Patent Decisions May Not Affect Stocks
• Trump's Upset Win Puts Obama Legacy On Chopping Block
• After Trump's Triumph, What's Next?
• Trump Win Puts These 4 On High Court Shortlist
• GOP Retains Control Of Both Houses Of Congress
• Marijuana Ballots: Calif., Fla. Say Yes To Legal Pot
• Walgreens Hits Theranos With $140M Breach Of Contract Suit
• AMS Sanctioned Over Subpoenas In Pelvic Mesh MDL
• 10 Cases Picked For Next Bellwether In J&J Artificial Hip MDL
• 'Secondhand' Info Sinks Whistleblower's FCA Suit At 11th Circ.
• Senate Leaders Press 2 Fed. Agencies For EpiPen Reviews
• Pot Grower Can't Nix Tax Ruling On 5th Amendment Grounds
• Kyle Bass Praises PTAB Nix Of 'Absurd' Drug Patents
• Mylan Floats Biosimilar Of Mega-Blockbuster Herceptin
• Ex-Cyberonics Sales Rep Asks 1st Circ. To Revive FCA Case
• Shareholders Sue Cempra Over Pneumonia Drug Safety
• FTC Wins Dismissal Of Opana, Lidoderm Pay-For-Delay Suit
• SC Judge Says 70 Lipitor Suits Should Go Back To Calif.
• Nev. Judge Shuts Down Trump's Early Voting Suit
• The Firms Cashing In This Election Season
• Why The Candidates' BigLaw Bills Keep Rising
• Candid Advice From The Bench: Judges Are People Too
• Fed. Circ. Upholds Endo's PTAB Win In Amneal Patent Fight
• FTC Asks 1st Circ. To Reverse Momenta Antitrust Win
• How New EPA Hazardous Waste Rule Impacts Retail Pharmacies
• Brexit And Supplemental Protection Certificates
• NuScience Says Atty's Vow To 'Destroy' Co. Shows Malice
• Takeda Asks 1st Circ. Not To Revive Actos Kickback Suit
• Valeant To Pop Out Paragon To Quell FTC Antitrust Concerns
• CEO Of Defunct Pharma Co. Sued For $489K Russian Award
• Novartis Unit Engineers Seek Cert. In FLSA Classification Row
• Endo Faces Securities Suit Over Unit's Price-Fixing Probe
• Hyman Phelps Attacks FDA Over 'Broken Approval System'
• Justices' Guidance Still Needed On Pay-For-Delay Accords
• Citizens United Architect Predicts Future Finance Battles
• Clinton Trounces Trump In Donations From Biggest Of BigLaw
• Justices Won't Consider IP Suit Over Amylin Drug Promos
• Pakistani Nationals Sentenced In Drug-Shipping Scheme
• Senators Want Mylan To Pay DOD $50M In EpiPen Refunds
• Minn. Right For Provigil Pay-For-Delay Suit, United Says
• 7 Steps For Managing An Associate Who May Be Impaired
• Calif. Org. Cut Auritec Out Of HIV Research, Suit Says
• J&J Can't Boot Invokana Injury Case From Pa. Court
• High Court Won't Review Lamictal Pay-For-Delay Row
• Trump Vs. Clinton: Some Antitrust Predictions
• Couple Convicted After Meningitis Outbreak Ask For Probation
• FDA Panel Votes For Pneumonia Antibiotic Approval
• Fla. Attys Get The Buzz On Entering Cannabis Law Field
• Benefits Manager Escapes Blue Cross Hep C Coverage Suit
• NJ Bill Would Ban Drug Coupons When Generics Exist
• Deals Rumor Mill: Warburg Pincus, Arrium, Endo International
• 3 Firms To Lead IPOs Totaling $80M As Election Slows Deals
• Ex-Greene LLP Partner Says Firm Owes Him Millions
• Katten Says Slew Of Sought Shkreli Docs Likely Privileged
• Health Hires: Hall Render, Lewis Brisbois, DeCotiis
• Lawmakers Call On Feds To Investigate Insulin Pricing
• Law Confusion No Reason To Ax Meningitis Suits, Court Told
• 2nd Circ. Won't Rehear Vitamin C Antitrust Decision
• Learned Intermediary Rule Prevails In Wisconsin Decision
• Brand Battles: Wal-Mart, Bristol-Myers, Adidas, FC Barcelona
• Health Care Provider Says Pharma Cos. Fixed Saline Prices
• FDA Inspectors Letting Loose On Defiant Drugmakers
• PTAB Upholds Patent For Horizon's Urine Disorder Drug
• Sloan-Kettering Says Niro Attys Filched Gene Therapy Docs
• Avalanche Biotechnologies Escapes IPO Suit Over Eye Drug
• The Role Of Litigation Analytics In Your Case
• Rainmaker Q&A: Schiff Hardin's Imron Aly
• Lipitor Users Say Diabetes Claims Belong In Calif. Court
• DC Circ. Won't Revisit Takeda's Gout Drug Dispute With FDA
• Chamber Of Commerce Backs GSK In 3rd Circ. Drug Appeal
• Abbott Offers Fixes To Clear $25B St. Jude Deal In EU
• Novartis Asks Fed. Circ. To Revive MS Treatment Patent
• Amneal Fights Endo's PTAB Win At Fed. Circ.
• FDA Scolds Supernus Pharmaceuticals Over Video Claims
• Spinning Off In The Biotech And Pharmaceutical Industries
• Green Coffee Adman Must Disgorge $29M In Fake Ad Suit
• 2nd Circ. Backs Ban On 'Gray Market' Sale Of Abbott Test Strip
• Employees Can't Trim RICO Claims In Meningitis Outbreak Suit
• 'Made In USA' Vitamin Buyer's Class Cert. Bid Too Long
• OPINION: 3rd Circ. Should Rehear Product-Hopping Case
• Adapt Or Die: Law Firms In Tomorrow's Economy — Part 5
• Mylan's EpiPen Rebate Deal Is Unacceptable, W.Va. AG Says
• Wright Medical Technology Agrees To $240M Hip Implant Deal
• Valeant Hit With Chancery Suit Over Libido Drug Marketing
• Deals Rumor Mill: Valeant, Fujifilm, Takata
• Lipitor Diabetes Suits Against Pharmacy Booted From MDL
• New Developments In The Missouri Removal Wars
• ITC Judge Says Swedish Co.'s Radiotherapy Imports Flout IP
• 2016's Thriving M&A Market
• J&J Settlement Ends Latest Pa. Risperdal Case Before Trial
• Fed. Circ. Urged To Reinstate Stanford Fetal Testing Patent
• Valeant Confirms Salix Is Up For Sale
• 4 Ways To Get Associates Trial-Ready
• Adapt Or Die: Law Firms In Tomorrow's Economy — Part 4
• Bayer, Pfizer Agree To Judge's Deal In Bovine Drug IP Row
• Justices Question Viability Of Laches Defense In Patent Law
• Deals Rumor Mill: Valeant, Mubadala, Amtek
• Express Scripts Wants Pharmacies To Back Up Antitrust Suit
• U of Wis. Backs Promega In Patent-Export High Court Case
• FDA Warning Wire: Officials Blocked From Chinese Drug Plant
• Ex-Insys Manager Says Drug Testing Him Is Unconstitutional
• Pfizer Wants 15 Non-Calif. Plaintiffs Out Of Zoloft MDL
• Feds Can't Escape Pfizer's $8.3M Tax Refund Interest Suit
• Momenta Must Face Clot Drug Antitrust Row, 1st Circ. Told
• Drugmaker Wins Reconsideration Bid In Toxic Exposure Suit
• Adapt Or Die: Law Firms In Tomorrow's Economy — Part 3
• When Your Client Is The President: Part 8